anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject new improver comprising purine nucleoside and pyrimidine nucleoside as active ingredients, improving reduction in memory caused by senile dementia, having no adverse action. SOLUTION: This improver for reduction in memory comprises (A) a compound selected from purine nucleosides and (B) a compound selected from pyrimidine nucleosides as active ingredients. Inosine is used as the component A and cytidine and uridine are used as the component B. Thymidine and guanosine 5'-monophosphate disodium salt (5'-GMP-2Na) are preferably used as other nucleic acid constituent components. The components are preferably blended in the molar ratio of inosine/cytidine/uridine/5'GMP2NA/thymidine of 4:4:3:4:1. The objective improver is preferably made into an injection form suitable for intravenous dosage. The concentration of the active ingredients in the improver is preferably 2-8w/v%. A dose is preferably 1-20ml (30-620mg of the amount of the active ingredients) per adult daily in the case of an infection.
Ischemia-reperfusion injury (IRI) results in irreversible metabolic dysfunction and structural damage to tissues or organs, posing a formidable challenge in the field of organ implantation, cardiothoracic surgery, and general surgery. Glycogen synthase kinase-3β (GSK-3β) a multifunctional serine/threonine kinase, is involved in a variety of biological processes, including cell proliferation, apoptosis, and immune response. Phosphorylation of its tyrosine 216 and serine 9 sites positively and negatively regulates the activation and inactivation of the enzyme. Significantly, inhibition or inactivation of GSK-3β provides protection against IRI, making it a viable target for drug development. Though numerous GSK-3β inhibitors have been identified to date, the development of therapeutic treatments remains a considerable distance away. In light of this, this review summarizes the complicated network of GSK-3β roles in IRI. First, we provide an overview of GSK-3β's basic background. Subsequently, we briefly review the pathological mechanisms of GSK-3β in accelerating IRI, and highlight the latest progress of GSK-3β in multiorgan IRI, encompassing heart, brain, kidney, liver, and intestine. Finally, we discuss the current development of GSK-3β inhibitors in various organ IRI, offering a thorough and insightful reference for GSK-3β as a potential target for future IRI therapy.
The decision to treat an incidental finding in an asymptomatic patient results from careful risk-benefit consideration and is often challenging. One of the main aspects is after how many years the group who underwent the intervention and faced the immediate treatment complications will gain a treatment benefit over the conservatively managed group, which maintains a lower but ongoing risk. We identify a common error in decision-making. We illustrate how a risk-based approach using the classical break-even point at the Kaplan-Meier curves can be misleading and advocate for using an outcome-based approach, counting the cumulative number of lost quality-adjusted life years instead. In clinical practice, we often add together the yearly risk of the natural course up to the time point where the number equals the risk of the intervention and assume that the patient will benefit from an intervention beyond this point in time. It corresponds to the crossing of the Kaplan-Meier curves. However, because treatment-related poor outcome occurs at the time of the intervention, while the poor outcome in the conservative group occurs over a given time period, the true benefit of retaining more quality-adjusted life years in the interventional group emerges at a much later time. To avoid overtreatment of patients with asymptomatic diseases, decision-making should be outcome-based with counting the cumulative loss of quality-adjusted life years, rather than risk-based, comparing the interventional risk with the ongoing yearly risk of the natural course.
A nucleic acid construct is described which provides cell type-specific expression of a therapeutic transgene. The construct utilizes a cell type-specific promoter which drives expression of the transgene. A positive feedback loop is introduced through the addition of an amplification promoter element operably linked to the therapeutic transgene and by providing, either as part of the same construct, or in a different construct, a transcription activator for activating the amplification promoter element. In one embodiment, the amplification promoter element is a heat shock response element (HSE) and the transcription activator is HSF-1. The construct enables functional targeting of a therapeutic gene while avoiding undesirable effects in non-targeted cells, by combining sufficiently high-level expression to promote a desirable therapeutic outcome with exceptional tissue specificity. A series of promoter elements, constructs, vectors, and therapeutic approaches is presented for gene therapy of tumors such as melanoma and other genetic diseases.
In order to carry out daily life activities, independence of individuals should be insured. For this independence, it is necessary to have adequate balance and coordination. Without adequate balance and coordination, it is not possible to walk neither even to stand. Movement is the basic living unit of an organism. Balance and coordination are of great importance for smooth, fluid and convenient action. In the clinical settings individuals are given exercises in different ways to increase their balance and coordination to protect them from injuries and to gain their independence. Nowadays, in order to adapt to the future, technological devices that can analyze and improve balance and coordination are being developed. The adequacy of the devices or systems developed for this purpose is also discussed. Most of the systems available on market only provide balance training by moving the floor, while others aim to contribute to balance by stimulating joint proprioception with a vibrating ground. This project aims to develop equipments that will provide balance and coordination trainings to guide the user through visual, auditory and mechanical feedback, develop a software which will record, analyze and evaluate the trainings given while ensuring that this equipment works systematically, carry out clinical studies to investigate the effectiveness of this developed system in healthy people.
The invention provides a high blood pressure treating drug, relates to applications of celery seed, semen cassiae and the like in drugs or health, and belong to the field of natural drugs or health products, wherein the high blood pressure treating drug is characterized by comprising 10-20 g of celery seed, 15-20 g of semen cassiae, 15-20 g of lotus leaf, 30-40 g of fallopia multiflora (thunb.) harald, and 15-20 g of jujube. According to the present invention, the preparation method comprises drying celery seed in the sun, grinding the dried celery seed into powder, grinding semen cassia into powder, drying lotus leaf in the sun, grinding the dried lotus leaf into powder, drying fallopia multiflora (thunb.) harald in the sun, grinding the dried fallopia multiflora (thunb.) harald into powder, drying jujube in the sun, grinding the dried jujube into powder, and mixing the powders according to the ratio, wherein about 20 g of the mixed powder is taken 3 times a day. The high blood pressure treating drug of the present invention has high medical value.
Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
BACKGROUND: Progestin-only pills (POPs) have been used for contraception in breastfeeding women for years. The existing guidelines allow the use of these contraceptives.
METHODS: Multicenter study with a single visit and retrospective data review. The study involved 100 women who used a drospirenone-only pill (DRSP) for contraception for at least 5 months during breastfeeding. The study aimed to analyze for those successful users the impact on new-born development, the bleeding profile and evaluate user satisfaction.
RESULTS: Analysis of the newborns showed that their growth parameters length and weight, were within the expected range of standard development. The mean birth weight was 3368 g, with the lowest recorded weight being 2860 g and the highest 5040 g. The median length of the newborns was 55 cm, ranging from 35 to 65 cm. All new-borns demonstrated appropriate growth within the established percentiles. Acceptability with the bleeding profile was rated with a VAS score: the mean acceptability rating was 82.8. Women aged 35 years or older reported significantly higher acceptability compared to younger women (≥35 years: mean = 88.4, SD = 16.5; <35 years: mean = 80.3, SD = 20.2) (p = 0.02). Sixty-one patients (N = 61; 61.0%; 95% CI: 50.7 - 70.4%) expressed willingness to continue using DRSP after breastfeeding.
CONCLUSION: Among those patients who continued the use of the DRSP only-pill for 5 months, this study shows no negative impact for new-borns, with no clinical influence observed on their growth. Additionally, those users expressed high satisfaction with the bleeding profile of the pill.Clinical trial registration number: DRKS00028438 .
Particulate material comprising rough mesoporous hollow nanoparticles. The rough mesoporous hollow nanoparticles may comprise a mesoporous shell, the external surface of which has projections thereon, the projections having smaller sizes than the particle size. The particulate material may be used to deliver active agents, such as insecticides and pesticides. The active agents can enter into the hollow core of the particles and be protected from degradation by sunlight. The rough surface of the particles retains the particles on plant leaves or animal hair. Methods for forming the particles are also described. Carbon particles and methods for forming carbon particles are also described.
This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual \[5\]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
Participants with part in consent will be enrolled in a phase 1a study of SRN-001. Prior to initiation of treatment, participants will undergo several screening test for checking their condition of health. There is no specific test comparing with the general other clinical trial in healthy volunteers. They will be randomized into two groups, active drug and inactive placebo(normal saline) as ratio 2:1. Starting dose is planned 15mg. For confirming maximal tolerable dose, dose will be escalated when no dose-limiting toxicity (DLT) confirmed. Each cohort will take single dose and for 4 weeks, safety observation will be taken. If safety abnormality will be retained in 4 weeks, the participant's safety observation will be prolonged by the end of the adverse event once 2 weeks.
The invention provides miRNA-disease association prediction based on graph neural networks. The traditional neural network model cannot process irregular non-European spatial data in the miRNA-disease associated prediction field. Therefore, the graph SAGE model is selected to extract the characteristics of the graph nodes. First we map the integrated disease similarity, integrated miRNA similarity to the same feature space and use known association data to construct miRNA-disease bipartite graphs as input for GraphSAGE. Information of neighbor nodes is aggregated through a GraphSAGE model, node feature representation is enriched, and effective data are provided for a downstream prediction task. And finally, performing weighted splicing on the learned miRNA and the potential characteristics of the diseases to serve as the input of a deep neural network prediction model, and obtaining the association score. The training model parameters are propagated back using the cross entropy loss function.
The present invention relates to medicine for treating cerebral infarction and a preparation method thereof, which belong to the technical field of the traditional Chinese medicine. The present invention provides medicine which has the advantages of better therapeutic effect, safety and no toxic and side effect and is used for treating cerebral infarction and a preparation method thereof. The present invention has the essential technical scheme that the medicine for treating the cerebral infarction is a medicament which is prepared from the following raw materials: 20 to 30 parts by weight of astragalus root, 10 to 20 parts by weight of grassleaf sweetflag rhizome, 10 to 20 parts by weight of hemlock parsley, 10 to 20 parts by weight of earthworm, 10 to 20 parts by weight of corydalis tuber, 20 to 30 parts by weight of water plantain and 20 to 30 parts by weight of suberect spatholobus. By the emergent toxicity test of animals, the medicine has the advantages of low toxicity and safe clinical application; the medicine proves that the medicine has better therapeutic effects on hemiplegia, weakness, mouth-eye deflection, unclear speech, hypomnesis, oppression in chest, palpitation, short breath weakness, etc. which are caused by cerebral infarction, coronary heart diseases, angina pectoris, myocardial infarction, etc. by clinic treatment.
Methods and artificial matrices for the growth and implantation of cartilaginous structures and surfaces are disclosed. In the preferred embodiments, chondrocytes are grown on biodegradable, biocompatible fibrous polymeric matrices. Optionally, the cells are proliferated in vitro until an adequate cell volume and density has developed for the cells to survive and proliferate in vivo. One advantage of the matrices is that they can be cast or molded into a desired shape, on an individual basis, so that the final product closely resembles a patient's own ear or nose. Alternatively, flexible matrices can be used which can be manipulated at the time of implantation, as in a joint, followed by remodeling through cell growth and proliferation in vivo. The cultured cells can also be maintained on the matrix in a nutrient media for production of bioactive molecules such as angiogenesis inhibiting factor.
Teratogenic Effects. Pregnancy Category B

Reproduction studies have been performed in rats and mice at doses up to moderately maternally toxic dose concentrations (i.e., 200 mg/kg/day by the oral route). These doses, based on a mg/m 2 basis, are estimated to be 4 and 2 times, respectively, the human daily dose of 500 mg by the oral route. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.
Cytotoxic agents (I) comprise an immunoglobulin (Ig), specific for the antigens on the surface of the cells which it is intended to kill, to which are covalently bonded 1-10 molecules of a polymeric carrier (VP) having covalently bonded to them in turn 5-500 molecules of a cytotoxic medicament (CD). (VP) has mol. wt. 5000-500000 and contains COOH, NH2 or cycloimidocarbonate gps. for forming the covalent bonds, and (CD) also has NH2 or COOH gps. for forming these bonds. Used for treating neoplastic diseases. The CD/VP bonds are enzymatically cleared when (I) is attached to the target cell, so by use of particular Ig, large amts. of (CD) can be delivered to specific points. The toxicity of (CD) is much lower when bonded in (I) than when used as the free cpd.
Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
Intracerebral hemorrhage (ICH) is a severe and sudden medical condition caused by the rupture of blood vessels in the brain, leading to permanent damage to brain tissue and often resulting in functional disabilities or death in patients. Diagnosis and analysis of ICH typically rely on brain CT imaging. Given the urgency of ICH conditions, early treatment is crucial, necessitating rapid analysis of CT images to formulate tailored treatment plans. However, the complexity of ICH CT images and the frequent scarcity of specialist radiologists pose significant challenges. Therefore, we collect a dataset from the real world for ICH and normal classification and three types of ICH image classification based on the hemorrhage location, i.e., Deep, Subcortical, and Lobar. In addition, we propose a neural network structure, dual-task vision transformer (DTViT), for the automated classification and diagnosis of ICH images. The DTViT deploys the encoder from the Vision Transformer (ViT), employing attention mechanisms for feature extraction from CT images. The proposed DTViT framework also incorporates two multilayer perception (MLP)-based decoders to simultaneously identify the presence of ICH and classify the three types of hemorrhage locations. Experimental results demonstrate that DTViT performs well on the real-world test dataset.
A retrospective, non-invasive monocentric study of our Hospital 10-year registry (including data on MRI angiography and Vascular Doppler Ultrasound) of patients who have already undergone coil embolization of pelvic gonadal vein in treatment of pelvic congestion syndrome. These patients will be contacted by phone to participate in the study. An information letter will be handed out and the study protocol will be explained to the patients. After obtaining their written consent, they will be asked to fill out the study's validated questionnaire at home and return it to us through pre-paid regular mail. A face to face interview with the patient will be scheduled to assess the correlation between patient's clinical symptoms and survey results. There will be no change in patient's routine follow-up care.

All physician investigators of the study are experts in their field of medicine (e.g. interventional MRI angiography, vascular disease).
Pain is an unpleasant sensory or emotional experience associated with actual or potential tissue damage and is classified as acute or chronic. Acute pain is felt for a short time after an injury or harmful stimulus and is considered part of a defense strategy; It points to an active danger to the organism. Chronic pain that exceeds the duration of the injury or trigger stimulus and lasts for at least three months. Recent studies show that chronic pain has devastating effects on cognitive functions by causing emotional stress, anxiety, and depression. Studies show that chronic pain affects certain cognitive areas. These areas are; processing speed, short-term memory, long-term memory, inhibitory control and working memory. In addition, task-oriented studies show that chronic pain affects not simple tasks, but rather dual tasks that require the use of complex cognitive function (executive function).

Task; it is a behavior, skill or ability that needs to be done. The simple (single) task contains only one alert or task. For example, walking. Dual task requires the simultaneous performance of two different tasks that can be measured independently and have different goals. For example, calculating while walking at the same time. In rehabilitation approaches, single or dual task trainings are applied. Among physiotherapy and rehabilitation approaches, single task training consists only of exercises involving motor performance; Dual task trainings can consist of different exercise combinations that require two different tasks to be performed at the same time as motor + motor, cognitive + cognitive or motor + cognitive performances. The clinical benefit of dual task training is that most of the daily living activities are done in dual task conditions.

Chronic pain is a common health problem associated with most rheumatic diseases. It is pain that lasts for at least 3 months and cannot be completely relieved with standard pain medication. 40-60% of rheumatologic patients do not have sufficient relief in their pain. For this reason, dual-task performance may be affected in individuals diagnosed with rheumatological disease, secondary to the impairment of cognition. In the literature, there are only limited studies showing dual-task performance effects in individuals diagnosed with fibromyalgia and osteoarthritis. However, chronic pain is the main health problem that prevents mobility restriction and participation in all rheumatic diseases. In addition, there is no study investigating the dual task performance effect in rheumatic diseases in a comprehensive way. Therefore, the aim of thestudy is to investigate the effect of rheumatic diseases on dual-task performance by comparing it with the control group.
Acupuncture has obvious therapeutic effect on intracerebral hemorrhage (ICH). miR-34a-5p regulated by acupuncture was found to attenuate neurological deficits in ICH. However, the underlying mechanisms are unclear. Ubiquitin-like 4A (UBL4A) has not been studied in ICH. SD rats were injected with autologous blood to induce ICH and treated with Baihui-penetrating-Qubin acupuncture. Acupuncture resulted in an increase in forelimb placing test scores, and a decrease in corner test scores and brain water content of ICH rats. Histopathological examination showed that acupuncture inhibited ICH-induced inflammation, decreased damaged neurons and increased UBL4A expression. UBL4A overexpression increased cell viability, inhibited apoptosis, reduced reactive oxygen species (ROS) level and increased manganese superoxide dismutase (MnSOD) activity, mitochondrial membrane potential and mtDNA level in rat embryonic primary cortical neurons. miR-34a-5p knockdown increased UBL4A expression, apoptosis rate and ROS level in hemin-treated neurons. Dual luciferase assays showed that miR-34a-5p bound to UBL4A. Apoptotic cells and ROS level were increased in hemin-treated neurons with UBL4A and miR-34a-5p knockdown. We firstly demonstrate the inhibitory effect of UBL4A on neuronal apoptosis, and the regulation relationship between UBL4A and miR-34a-5p. This study provides a new candidate target for ICH treatment and more basis for elucidating the molecular mechanism of acupuncture. In the future, we will conduct a deeper exploration of the effects of UBL4A on ICH.